EP1128738B1 - A method for supplying bioavailable methionine to a cow - Google Patents

A method for supplying bioavailable methionine to a cow Download PDF

Info

Publication number
EP1128738B1
EP1128738B1 EP99972074A EP99972074A EP1128738B1 EP 1128738 B1 EP1128738 B1 EP 1128738B1 EP 99972074 A EP99972074 A EP 99972074A EP 99972074 A EP99972074 A EP 99972074A EP 1128738 B1 EP1128738 B1 EP 1128738B1
Authority
EP
European Patent Office
Prior art keywords
ester
methionine
cow
hydroxy analogue
isopropyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99972074A
Other languages
German (de)
French (fr)
Other versions
EP1128738B9 (en
EP1128738A1 (en
Inventor
Jean-Claude Robert
Robert Bennett
Georges Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adisseo Ireland Ltd
Original Assignee
Adisseo Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26234645&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1128738(B1) "Global patent litigation datasetā€ by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9814249A external-priority patent/FR2785772B1/en
Application filed by Adisseo Ireland Ltd filed Critical Adisseo Ireland Ltd
Priority to DK04010767.4T priority Critical patent/DK1442664T3/en
Priority to EP04010767A priority patent/EP1442664B1/en
Publication of EP1128738A1 publication Critical patent/EP1128738A1/en
Application granted granted Critical
Publication of EP1128738B1 publication Critical patent/EP1128738B1/en
Publication of EP1128738B9 publication Critical patent/EP1128738B9/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Definitions

  • the present invention relates to a method for supplying bioavailable methionine to a cow which comprises administering to the cow an ester of the hydroxy analogue of methionine.
  • the present invention also relates to a method of improving milk obtained from dairy cows and in particular to a method which comprises supplying to the diary cow an ester of the hydroxy analogue of methionine.
  • Protein is one of the major nutrients in the diets of lactating cows. The cows however do not actually require proteins but instead they require the specific amino acids, which are the building blocks that make up their own protein.
  • methionine is a limiting amino acid and in particular for milk production it is believed that a well balanced level of methiouine will result in effective levels of milk production. It is also believed that an increase in methionine levels can result in increased milk production.
  • Methionine can be added directly to the cow's diet.
  • the free form of this amino acid is rapidly degraded by bacteria in the rumen and consequently only a small portion of the methionine enters the bloodstream.
  • methionine is introduced into the diet in a protected or modified form, permitting the compound to pass through the rumen unaffected.
  • the methionine released from the protected or modified form then enters the small intestine and is absorbed into the bloodstream.
  • One of the most widely studied compounds for this particular purpose is the hydroxy analogue of methionine, namely 2-hydroxy-4-(methylthio) butanoic acid, generally refered to as HMB.
  • US-A-4,388,327 discloses a method of increasing milk production of dairy cows with the hydroxy analog of methionine and its esters.
  • WO 99/04647 published on 4 th February 1999, discloses a method of introducing methionine into the rumen by supplementing the feed with the hydroxy analogue of methionine.
  • the hydroxy analogue is substantially unaffected by rumen degradation, passing through the rumen and consequently providing at least 20%, preferably at least 40% of the hydroxy analogue for absorption into the bloodstream through the intestine.
  • the patent application refers to the hydroxy analogue, its salts, esters, amides and oligomers as being 'rumen by-pass' and claims an improved efficient means of introducing methionine into the bloodstream of the cow.
  • the claimed advantage of the disclosed compounds in this documents is that the compounds by-pass the rumen and are absorbed in the intestine.
  • the best determination of the absorption of the hydroxy analogue of methionine is the determination of the bioavailability in the blood.
  • the bioavailability is characterised by the level of appearance of methionine in the blood compared with the amount of methionine equivalent of compound introduced into the feed ration. This determination takes into account the passage of the hydroxy analogue through the rumen, its degree of absorption irrespective of the place of absorption during the digestive transit and the degree enzymatic conversion of the hydroxy analogue into methionine.
  • methionine protected against degradation in the rumen with a polymer in particular the product sold under the trade name SmartamineTM, has a rumen by-pass of 90%; the hydroxy analogue gives a bioavailability of only 3%.
  • a paper in J Dairy Science 1988, 71, pp3292 to 3301 discloses the introduction of the methyl ester or the ethyl ester of the hydroxy analogue of methionine to the diet of a cow in an attempt to increase the level of milk production.
  • the results from the study indicate that these esters are rapidly converted to the hydroxy analogue of methionine and subsequently degraded in the rumen of the animal. Specifically, after incubation for six hours in rumen juices, only 1.8% and 3% of the methyl and ethyl ester of the hydroxy analogue respectively, remains. This is compared with 34% and 85% of methionine and the hydroxy analogue of methionine.
  • the present invention provides a method for supplying bioavailable methionine to a cow which comprises administering to the cow an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
  • cow is meant cattle, namely beef cows and dairy cows.
  • the use of the claimed ester provides the advantage over the prior art in that it provides a greater amount of methionine into the bloodstream of the cow than the methionine derivatives of the prior art. Furthermore, we have surprisingly found that the use of the particular ester results in very rapid absorption of methionine into the bloodstream.
  • the ester derivative according to the present invention appears not only to avoid rumen degradation but surprisingly to introduce methionine into the bloodstream by absorption through the rumen wall. This is contrary to the aforementioned prior art wherein the hydroxy analogue compounds of methionine are known to either degrade in the rumen or by-pass the rumen and absorb through the intestine.
  • the present invention also seeks to provide an improvment in the condition of the cow and the use of the specific ester of the present invention can result in an improvment in the weight gain, an improvement in the fertility, an increase in energy as well as an improvement in the function of the liver.
  • the effect on the liver function as a result of the administration of the ester is an important benefit. This effect may be characterised by a reduction in metabolic problems through an improvement in the very low density lipoproteins. Also thought likely, is a reduction in blood ketosis and a limitation of hepatic steatosis.
  • the administration of the ester can also have a beneficial effect on reproduction.
  • the interval between calving and reproduction may be shortened. This effect is also characterised by an increase in the percentage fertilisation during insemination.
  • a method of improving milk from a dairy cow which comprises administering to the cow an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
  • ester of the present invention is supplied to dairy cows we have found that by supplementing the normal daily feed of the dairy cow with the isopropyl ester of the hydroxy analogue of methionine, there is a surprising improvement in the quality of the milk obtained from the dairy cow. In particular, we have found that the introduction of the specific ester into the diet of the diary cow results in an increase in the protein content of the milk.
  • the increase in protein content as a result of the administration of the ester can be evaluated as being generally between 0.5 and 4g of protein per litre of milk.
  • the proteins which are generally increased are alpha, beta and kappa, especially the beta and kappa proteins which have a favourable effect on the cheese making properties of the milk produced.
  • the use of the isopropyl ester of the hydroxy analogue of methionine is particularly effective, being capable of providing at least 50% of methionine equivalent to the bloodstream by absorption across the rumen wall.
  • the isopropyl ester of the hydroxy analogue of methionine has been found to display a biovailablity of methionine of more than 50%.
  • the ester may be supplied to the cow in any suitable way.
  • the ester is supplied as a feed supplement and may be supplied to the cow through the normal daily feed.
  • Cows are fed a ration which comprises a concentrate portion and a forage portion.
  • a ration comprising a forage portion, a concentrate portion and a supplement, said supplement comprising an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
  • a preferred ration comprises a forage portion, a concentrate portion and the isopropyl ester of the hydroxy analogue of methionine.
  • the amount of ester introduced into the feed of the cow may vary from the breed of cow and from the stage of the milk producing cycle.
  • the supplement comprises an amount of ester calculated as methionine equivalent of up to 75g, preferably from 5 to 50g, especially from 10 to 30g per animal per day.
  • the amount of ester required may be calculated using any suitable means familiar to the person skilled in the art.
  • the amount may be determined through the use of a computer model.
  • the isopropyl ester of the hydroxy analogue of methionine may be present in a concentration of from 7 to 65g per animal per day, most preferably from 10 to 30g per animal per day of ester.
  • a unit dosage form comprising an ester which ester is the isopropyl ester of the hydroxy analogue of methionine suitable for dosage for one cow for one day.
  • the forage portion may typically comprise corn silage, grass silage, alfalfa silage and/or hay silage.
  • the concentrate portion may typically comprise grains such as corn, wheat, barley in addition to sources of protein such as meal, rape seed, soyabean, corn gluten and by products such as fish meal, blood meal, brewers grain and the like.
  • the supplement comprising the ester may be mixed with the forage portion and the grain portion at any suitable time.
  • the ester is a liquid and may be introduced by mixing in with the forage portion and the concentrate portion prior to the formation of the food pellets. Alternatively, the ester may be added to the pellet ration by the farmer prior to feeding to the cow.
  • the ester when incorporated into the feed pellet either before or after formation of the pellet is stable. It has been found that the isopropyl ester of the hydroxy analogue is stable in the resulting pellet, retaining over 95% stability over a long period. Thus, the use of the ester of the present invention as a food supplement provides a stable source of methionine.
  • reaction mixture was then neutralised with 161.2g of 32% aqueous ammonia (2.72 mol of ammonia). Two phases were obtained. 780g of water and 449.7g of dichloromethane were added. The two resulting phases were separated to yield 939.1g of organic phase and 1247.4g of aqueous phase.
  • the light fractions of the organic product were removed by distillation.
  • the temperature of the evaporating bath was increased and the pressure reduced to approximately a few milibars. 263.5g of distillate was recovered.
  • the titre of isopropyl ester was found to be greater than 99%.
  • the yield was 72%.
  • the concentration of methionine and HMB was measured over a period of 27 hours. The measurements were plotted and the areas under the curve calculated to provide the bioavailability results.
  • Bioavailability was determined with reference to SmartamineTM.
  • the kinetics of availability of methionine and HMB in the bloodstream were determined for the isopropyl ester of the hydroxy analogue of methionine and compared with the hydroxy analogue of methionine (a compound not according to the present invention).
  • Example 2 The procedure of Example 2 was repeated wherein samples of the isopropyl ester of the hydroxy analogue (69g) and the hydroxy analogue (AlimetTM -57g) were given to four cows. The methionine and HMB levels in the blood plasma taken from the cows were analysed and the results are given in Tables 3 and 4 below.
  • the isopropyl ester of the hydroxy analogue of methionine was given to 16 cows over a period of 8 weeks. Each cow was given daily corn silage and a supplement to cover 100% of requirement and a 115% PDIE (protein digestible in the intestine) requirement.
  • the daily supplement consisted of 4.3 kg of a high energy concentrate which consists of 19.8% barley, 21.1% wheat, 37.5% beet pulp, 2.3% animal fat, 1.1% salts, 0.6% calcium carbonate and 1.1% sodium bicarbonate; 2.2 kg of tanned soya cake, 1kg of normal soya cake, 240g of urea and 300g of vitamin and mineral supplements.
  • the method according to the present invention was carried out by splitting the cows into three groups and giving the following supplement to the normal diet to provide 12.5g of bioavailable methionine per animal per day.
  • Example 4 The procedure of Example 4 was repeated and observations on the liver function and fertility of the cows were made. Substantial improvements were observed in the cows receiving the ester.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

The present invention relates to a method for supplying bioavailable methionine to a cow which comprises administering to the cow an ester of the hydroxy analogue of methionine. The present invention also relates to a method of improving milk obtained from dairy cows and in particular to a method which comprises supplying to the diary cow an ester of the hydroxy analogue of methionine.
Protein is one of the major nutrients in the diets of lactating cows. The cows however do not actually require proteins but instead they require the specific amino acids, which are the building blocks that make up their own protein.
It is known that methionine is a limiting amino acid and in particular for milk production it is believed that a well balanced level of methiouine will result in effective levels of milk production. It is also believed that an increase in methionine levels can result in increased milk production.
It is therefore desirable to maintain or even enhance the level of methionine. Methionine can be added directly to the cow's diet. However, the free form of this amino acid is rapidly degraded by bacteria in the rumen and consequently only a small portion of the methionine enters the bloodstream. There have been many attempts to overcome this problem and in general the methionine is introduced into the diet in a protected or modified form, permitting the compound to pass through the rumen unaffected. The methionine released from the protected or modified form then enters the small intestine and is absorbed into the bloodstream. One of the most widely studied compounds for this particular purpose is the hydroxy analogue of methionine, namely 2-hydroxy-4-(methylthio) butanoic acid, generally refered to as HMB.
FR-A-2 305 938 or J. A. Ayoade et al., in "Studies on methionine derivatives as possible sources of protected methionine in ruminant rations", Journal of the Science of Food and Agriculture, GB, Elsevier Applied Science Publishers Barking, 33 (10), 1982, pages 949-956 ISSN: 0022-5142 discloses a ration comprising an ethyl ester of N-acetyl-L-methionine.
US-A-4,388,327 discloses a method of increasing milk production of dairy cows with the hydroxy analog of methionine and its esters.
WO 99/04647, published on 4th February 1999, discloses a method of introducing methionine into the rumen by supplementing the feed with the hydroxy analogue of methionine. In this patent application, it is claimed that the hydroxy analogue is substantially unaffected by rumen degradation, passing through the rumen and consequently providing at least 20%, preferably at least 40% of the hydroxy analogue for absorption into the bloodstream through the intestine. The patent application refers to the hydroxy analogue, its salts, esters, amides and oligomers as being 'rumen by-pass' and claims an improved efficient means of introducing methionine into the bloodstream of the cow. The claimed advantage of the disclosed compounds in this documents is that the compounds by-pass the rumen and are absorbed in the intestine.
There are also many publications on the effect of the hydroxy analogue of methionine and a publication by Charles Schwab, from a presentation given at a conference in May 1998, reviews all of the publications and concludes that the hydroxy analogue of methionine is thought to by-pass the rumen for intestinal absorption but will only do so if it is administered at a dose above 60g per animal per day, preferably above 90g per animal per day. At lower doses, it would appear, according to the author, that the hydroxy analogue of methionine is to a large extent, consumed by the micro organism in the rumen.
The best determination of the absorption of the hydroxy analogue of methionine is the determination of the bioavailability in the blood. The bioavailability is characterised by the level of appearance of methionine in the blood compared with the amount of methionine equivalent of compound introduced into the feed ration. This determination takes into account the passage of the hydroxy analogue through the rumen, its degree of absorption irrespective of the place of absorption during the digestive transit and the degree enzymatic conversion of the hydroxy analogue into methionine. At a dose of methionine equivalent to 50g per day per cow, it is described in this article that methionine protected against degradation in the rumen with a polymer, in particular the product sold under the trade name Smartamineā„¢, has a rumen by-pass of 90%; the hydroxy analogue gives a bioavailability of only 3%.
A paper in J Dairy Science 1988, 71, pp3292 to 3301 discloses the introduction of the methyl ester or the ethyl ester of the hydroxy analogue of methionine to the diet of a cow in an attempt to increase the level of milk production. The results from the study indicate that these esters are rapidly converted to the hydroxy analogue of methionine and subsequently degraded in the rumen of the animal. Specifically, after incubation for six hours in rumen juices, only 1.8% and 3% of the methyl and ethyl ester of the hydroxy analogue respectively, remains. This is compared with 34% and 85% of methionine and the hydroxy analogue of methionine.
We have now found, contrary to the teachings of the aforementioned prior art, that a certain ester of the hydroxy analogue of methionine has a favourable effect in cows. We have surprisingly found that the compound introduces methionine into the bloodstream of the rumen more effectively and more rapidly than the known prior art. We have also found that this particular compound does not enter the bloodstream through rumen by-pass and intestinal absorption but by absorption through the rumen wall. We have also found that introducing the specific ester compound into the diet of dairy cows through the feed ration results in desired improvement in milk production.
Accordingly the present invention provides a method for supplying bioavailable methionine to a cow which comprises administering to the cow an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
For the purposes of the present invention, by cow is meant cattle, namely beef cows and dairy cows.
The use of the claimed ester provides the advantage over the prior art in that it provides a greater amount of methionine into the bloodstream of the cow than the methionine derivatives of the prior art. Furthermore, we have surprisingly found that the use of the particular ester results in very rapid absorption of methionine into the bloodstream. The ester derivative according to the present invention appears not only to avoid rumen degradation but surprisingly to introduce methionine into the bloodstream by absorption through the rumen wall. This is contrary to the aforementioned prior art wherein the hydroxy analogue compounds of methionine are known to either degrade in the rumen or by-pass the rumen and absorb through the intestine.
As is evident from the prior art in this area, studies to introduce methionine into the bloodstream of the ruminant have concentrated on the use of rumen by-pass compounds as the quickest and most effective means of introducing methionine into the bloodstream. We have found that the addition of the ester of the present invention to the diet of the cow can result, in some cases, in more than 50% of methionine equivalent being absorbed directly through the rumen wall. Not only does this ester have a high bioavailability level but it allows methionine or biologically equivalent compounds to enter the bloodstream very quickly after intake by the cow through rumen absorption. This result is surprising and quite unexpected because until now, it has actually been believed that only compounds such as volatile fatty acids, ammonia and dioxycarbons are absorbed through the rumen wall.
The present invention also seeks to provide an improvment in the condition of the cow and the use of the specific ester of the present invention can result in an improvment in the weight gain, an improvement in the fertility, an increase in energy as well as an improvement in the function of the liver.
The effect on the liver function as a result of the administration of the ester is an important benefit. This effect may be characterised by a reduction in metabolic problems through an improvement in the very low density lipoproteins. Also thought likely, is a reduction in blood ketosis and a limitation of hepatic steatosis.
The administration of the ester can also have a beneficial effect on reproduction. The interval between calving and reproduction may be shortened. This effect is also characterised by an increase in the percentage fertilisation during insemination.
It also appears that the use of the specific ester may result in a stimulation of rumen fermentation, thus resulting in more digestible organic matter and therefore more energy.
We have also found that when the ester of the present invention is given to dairy cows, there is an improvement in the milk obtained thereof.
According to another aspect of the present invention, there is provided a method of improving milk from a dairy cow which comprises administering to the cow an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
Where the ester of the present invention is supplied to dairy cows we have found that by supplementing the normal daily feed of the dairy cow with the isopropyl ester of the hydroxy analogue of methionine, there is a surprising improvement in the quality of the milk obtained from the dairy cow. In particular, we have found that the introduction of the specific ester into the diet of the diary cow results in an increase in the protein content of the milk.
Furthermore, in addition to the protein level, it has been found that the administration of the isopropyl ester of the hydroxy analogue of methionine can result in improvements in the volume of milk produced and the fat content of the milk.
The increase in protein content as a result of the administration of the ester can be evaluated as being generally between 0.5 and 4g of protein per litre of milk. The proteins which are generally increased are alpha, beta and kappa, especially the beta and kappa proteins which have a favourable effect on the cheese making properties of the milk produced.
The foregoing objects may be obtained in whole or in part.
It has been found that the use of the isopropyl ester of the hydroxy analogue of methionine is particularly effective, being capable of providing at least 50% of methionine equivalent to the bloodstream by absorption across the rumen wall. The isopropyl ester of the hydroxy analogue of methionine has been found to display a biovailablity of methionine of more than 50%.
Furthermore it has been found that with the isopropyl ester of the hydroxy analogue, the bioavailability peak appears in the blood relatively quickly following the administration indicating, that the ester is absorbed directly through the rumen wall thus indicating that the ester is not rumen by-pass.
The ester may be supplied to the cow in any suitable way. Preferably, the ester is supplied as a feed supplement and may be supplied to the cow through the normal daily feed. Cows are fed a ration which comprises a concentrate portion and a forage portion. According to another aspect of the present invention there is provided a ration comprising a forage portion, a concentrate portion and a supplement, said supplement comprising an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
A preferred ration comprises a forage portion, a concentrate portion and the isopropyl ester of the hydroxy analogue of methionine.
The amount of ester introduced into the feed of the cow may vary from the breed of cow and from the stage of the milk producing cycle. Suitably, the supplement comprises an amount of ester calculated as methionine equivalent of up to 75g, preferably from 5 to 50g, especially from 10 to 30g per animal per day.
The amount of ester required may be calculated using any suitable means familiar to the person skilled in the art. Suitably, the amount may be determined through the use of a computer model.
The isopropyl ester of the hydroxy analogue of methionine may be present in a concentration of from 7 to 65g per animal per day, most preferably from 10 to 30g per animal per day of ester.
According to another aspect of the present invention there is provided a unit dosage form comprising an ester which ester is the isopropyl ester of the hydroxy analogue of methionine suitable for dosage for one cow for one day.
The forage portion may typically comprise corn silage, grass silage, alfalfa silage and/or hay silage. The concentrate portion may typically comprise grains such as corn, wheat, barley in addition to sources of protein such as meal, rape seed, soyabean, corn gluten and by products such as fish meal, blood meal, brewers grain and the like.
The supplement comprising the ester may be mixed with the forage portion and the grain portion at any suitable time. The ester is a liquid and may be introduced by mixing in with the forage portion and the concentrate portion prior to the formation of the food pellets. Alternatively, the ester may be added to the pellet ration by the farmer prior to feeding to the cow.
The ester when incorporated into the feed pellet either before or after formation of the pellet is stable. It has been found that the isopropyl ester of the hydroxy analogue is stable in the resulting pellet, retaining over 95% stability over a long period. Thus, the use of the ester of the present invention as a food supplement provides a stable source of methionine.
The present invention will now be described in detail with reference to the following examples.
EXAMPLE 1:- ISOPROPYL ESTER OF THE HYDROXY ANALOGUE OF METHIONINE (a) PREPARATION OF THE ESTER: (1) isopropyl ester of the hydroxy analogue of methionine.
314.4g (1.88mol) of 2 hydroxy-4 methylthio-butyronitrile was placed in a stirred jacket reactor fitted with chicanes. 201.3g (1.951 mol) of 95% sulphuric acid was added slowly whilst maintaining the temperature below 50Ā°C. After the introduction of the acid, the reaction temperature was maintained at 45Ā°C for 15 minutes. 227.3g of isopropanol was added to the reactor contents. The temperature of the reactor was then increased at a rate of 5Ā°C per minute until the temperature at the bottom of the reactor reached 116Ā°C and the temperature at the top reached 75 Ā°C. These reactor conditions were maintained for 5 hours. Some of the distillate was removed during that period and replaced with fresh isopropanol.
The reaction mixture was then neutralised with 161.2g of 32% aqueous ammonia (2.72 mol of ammonia). Two phases were obtained. 780g of water and 449.7g of dichloromethane were added. The two resulting phases were separated to yield 939.1g of organic phase and 1247.4g of aqueous phase.
The light fractions of the organic product were removed by distillation. The temperature of the evaporating bath was increased and the pressure reduced to approximately a few milibars. 263.5g of distillate was recovered. The titre of isopropyl ester was found to be greater than 99%. The yield was 72%.
(b) BIOAVAILABILITY
Spot doses of the following amount of the ester prepared as detailed above, equating to 50g of methionine equivalent, were given to 2 cows in the manner described in Example 2(b1) above.
ā€ƒā€ƒā€ƒisopropyl ester of HMB: 80.5g
The concentration of methionine and HMB was measured over a period of 27 hours. The measurements were plotted and the areas under the curve calculated to provide the bioavailability results.
Bioavailability was determined with reference to Smartamineā„¢.
The bioavailability results of the ester are given in Table 1
Figure 00100001
EXAMPLE 3 : KINETICS
The kinetics of availability of methionine and HMB in the bloodstream were determined for the isopropyl ester of the hydroxy analogue of methionine and compared with the hydroxy analogue of methionine (a compound not according to the present invention).
The procedure of Example 2 was repeated wherein samples of the isopropyl ester of the hydroxy analogue (69g) and the hydroxy analogue (Alimetā„¢ -57g) were given to four cows. The methionine and HMB levels in the blood plasma taken from the cows were analysed and the results are given in Tables 3 and 4 below.
It can be seen from the results that the isopropyl ester of the hydroxy analogue of mechioniae provides methonine and HMB to the bloodstream much quicker than HMB itself, thus indicaring the ester is absorbed through the rumen wall.
Figure 00120001
Figure 00130001
EXAMPLE 4. : MILK PRODUCTION Example (a) Isopropyl ester of the hydroxy analogue of methionine and the isopropyl ester of methionine
The isopropyl ester of the hydroxy analogue of methionine was given to 16 cows over a period of 8 weeks. Each cow was given daily corn silage and a supplement to cover 100% of requirement and a 115% PDIE (protein digestible in the intestine) requirement. The daily supplement consisted of 4.3 kg of a high energy concentrate which consists of 19.8% barley, 21.1% wheat, 37.5% beet pulp, 2.3% animal fat, 1.1% salts, 0.6% calcium carbonate and 1.1% sodium bicarbonate; 2.2 kg of tanned soya cake, 1kg of normal soya cake, 240g of urea and 300g of vitamin and mineral supplements.
The method according to the present invention was carried out by splitting the cows into three groups and giving the following supplement to the normal diet to provide 12.5g of bioavailable methionine per animal per day.
  • Treatment 1 : 1kg of soya cake
  • Treatment 2 : 1kg of soya cake 20g of polymer coated methionine (comparative example)
  • Treatment 3 : 1 kg of soya cake supplemented with 3 % isopropyl ester of HMBI containing 57% equivalent methionine
The supplements were given to the cows according to the following schedule:
PERIOD
Group D1 to D15 D15 to D30 D31 to D45 D46 to D60
1 Control without additive isopropyl ester of HMB Polymer-protected methionine
2 Control without additive Polymer-protected methionine isopropyl ester of HMB
3 isopropyl ester of HMB Polymer-protected methionine Control without additive
4 Polymer-protected methionine isopropyl ester of HMB Control without additive
The results from the analyses of the milk produced are given below in Table 5
RESULTS ON MILK PRODUCTION
COMPOUND Daily amount of milk (kg/cow) Butter Content of Milk g/kg Protein Content of Milk
Control 31.4 39.1 30.1
isopropyl ester of HMB 32.3 44.3 30.8
COMPARATIVE: Polymer-protected methionine 31.4 40.3 30.9
It can be seen from the results that the addition of the isopropyl ester of the hydroxy analogue of methionine to the diet of the cow results in milk with higher fat content and higher protein content.
EXAMPLE 5 LIVER AND FERTILITY
The procedure of Example 4 was repeated and observations on the liver function and fertility of the cows were made. Substantial improvements were observed in the cows receiving the ester.

Claims (15)

  1. A method for supplying bioavailable methionine to a cow which comprises administering to the cow an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
  2. A method as claimed in claim 1 in which the ester is introduced as a supplement to the feed.
  3. A method of supplying at least 50% bioavailable methionine to a cow which comprises administering to the cow the isopropyl ester of the hydroxy analogue of methionine.
  4. A method of improving milk obtained from a dairy cow which comprises supplying to the cow an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
  5. A method as claimed in claim 4 the improvement in which comprises increased protein content in the milk.
  6. A method as claimed in claim 4 the improvement in which comprises increased fat content in the milk.
  7. A ration comprising a grain portion, a concentrate portion and a supplement, said supplement comprising an ester which ester is the isopropyl ester of the hydroxy analogue of methionine.
  8. A ration as claimed in claim 7 in which the supplement comprises an amount of ester calculated as methionine equivalent of up to 75g.
  9. A ration as claimed in claim 8 comprising an amount of ester calculated as methionine equivalent of 10 to 30g.
  10. A ration as claimed in claim 7 wherein the isopropyl ester is present in an amount of from 7 to 65g per cow per day.
  11. A unit dosage form comprising an amount of an ester which ester is the isopropyl ester of the hydroxy analogue of methionine suitable for dosage for one cow for one day.
  12. A method of improving the condition of a cow which comprises supplying to the cow an ester which ester is the isopropyl ester of the hydroxy analogue of methionine, wherein the methods for treatment of the human or aminal body by surgery or therapy and diagnostic methods practised on the human or animal body are excluded.
  13. A method as claimed in claim 12 in which the improvement comprises improved fertility.
  14. A method as claimed in claim 12 in which the improvement comprises an increase in energy.
  15. Use of the isopropyl ester of the hydroxy analogue of methionine for the preparation of a feed supplement for improving liver function to a cow.
EP99972074A 1998-11-13 1999-11-10 A method for supplying bioavailable methionine to a cow Expired - Lifetime EP1128738B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK04010767.4T DK1442664T3 (en) 1998-11-13 1999-11-10 Method of supplying bioavailable methionine to a cow
EP04010767A EP1442664B1 (en) 1998-11-13 1999-11-10 A method for supplying biovailable methionine to a cow

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9814249A FR2785772B1 (en) 1998-11-13 1998-11-13 USE OF METHIONINE ESTERS IN ANIMAL NUTRITION
FR9814249 1998-11-13
FR9910050 1999-07-29
FR9910050A FR2785773B1 (en) 1998-11-13 1999-07-29 USE OF METHIONINE ESTERS IN ANIMAL NUTRITION
PCT/EP1999/009021 WO2000028835A1 (en) 1998-11-13 1999-11-10 A method for supplying bioavailable methionine to a cow

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04010767A Division EP1442664B1 (en) 1998-11-13 1999-11-10 A method for supplying biovailable methionine to a cow

Publications (3)

Publication Number Publication Date
EP1128738A1 EP1128738A1 (en) 2001-09-05
EP1128738B1 true EP1128738B1 (en) 2004-05-12
EP1128738B9 EP1128738B9 (en) 2004-11-24

Family

ID=26234645

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04010767A Expired - Lifetime EP1442664B1 (en) 1998-11-13 1999-11-10 A method for supplying biovailable methionine to a cow
EP99972074A Expired - Lifetime EP1128738B9 (en) 1998-11-13 1999-11-10 A method for supplying bioavailable methionine to a cow

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04010767A Expired - Lifetime EP1442664B1 (en) 1998-11-13 1999-11-10 A method for supplying biovailable methionine to a cow

Country Status (25)

Country Link
US (6) US6221909B1 (en)
EP (2) EP1442664B1 (en)
JP (1) JP4703853B2 (en)
KR (2) KR100756572B1 (en)
CN (1) CN1301660C (en)
AP (1) AP1812A (en)
AR (1) AR021264A1 (en)
AT (2) ATE482627T1 (en)
AU (2) AU775693B2 (en)
BR (2) BR9917851B1 (en)
CA (1) CA2348440C (en)
DE (2) DE69942808D1 (en)
DK (2) DK1442664T3 (en)
EA (1) EA002558B1 (en)
ES (1) ES2221486T3 (en)
FR (1) FR2785773B1 (en)
ID (1) ID30016A (en)
IL (2) IL142955A0 (en)
MA (1) MA25270A1 (en)
MX (1) MXPA01004747A (en)
NO (1) NO328761B1 (en)
NZ (1) NZ511427A (en)
PT (2) PT1128738E (en)
TR (1) TR200101323T2 (en)
WO (1) WO2000028835A1 (en)

Families Citing this family (18)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6017563A (en) 1997-07-25 2000-01-25 Novus International, Inc. Process for optimizing milk production
FR2785773B1 (en) 1998-11-13 2001-04-20 Rhone Poulenc Nutrition Animal USE OF METHIONINE ESTERS IN ANIMAL NUTRITION
EP1358805A1 (en) * 2002-04-30 2003-11-05 Aventis Animal Nutrition S.A. Animal feed supplement
US20040170669A1 (en) * 2002-07-19 2004-09-02 Kunkle William E. Feed rations and methods of feeding growing ruminants
ES2279719B1 (en) * 2006-01-26 2008-07-16 Timac Agro EspaƱa, S.A. NEW METABOLIC AND NUTRITIONAL ACTIVATOR FOR PLANTS.
US20070231377A1 (en) * 2006-03-28 2007-10-04 Novus International Inc. Compositions for promoting hair growth
WO2007147155A1 (en) * 2006-06-16 2007-12-21 Novus International Inc. Polyol ester compounds
DE102006055470A1 (en) * 2006-11-24 2008-05-29 Evonik Degussa Gmbh Ketomethionine ketals and their derivatives
US7704521B2 (en) * 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
DE102007062199A1 (en) 2007-12-21 2009-06-25 Evonik Degussa Gmbh 2-methylthioethyl-substituted heterocycles as feed additives
DE102009002044A1 (en) 2009-03-31 2010-10-07 Evonik Degussa Gmbh Dipeptides as feed additives
PL3795669T3 (en) * 2009-06-29 2024-03-18 Inolex Investment Corporation Non-petrochemically derived cationic emulsifiers that are neutralized amino acid esters and related compositions and methods
DE102010029399A1 (en) 2010-05-27 2011-12-01 Evonik Degussa Gmbh Cyclic dipeptides as feed additives
US9169203B2 (en) 2012-01-06 2015-10-27 Novus International, Inc. Sulfoxide-based surfactants
ES2703051T3 (en) * 2012-07-12 2019-03-06 Novus Int Inc Compositions of matrix and layer for the protection of bioactive agents
CN112707851A (en) 2015-11-12 2021-04-27 čÆŗ华äøå›½é™…č‚”ä»½ęœ‰é™å…¬åø Sulfur-containing compounds as solvents
US11185524B2 (en) * 2019-05-15 2021-11-30 Novus International, Inc. Means for protecting methionine hydroxy analog from rumen degradation
EP4025561A4 (en) * 2019-09-06 2024-01-31 Kemin Industries, Inc. Processes for the preparation of alpha-hydroxy esters by esterification of alpha-hydroxy acids

Family Cites Families (10)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
AU478542B2 (en) * 1973-03-20 1975-09-18 Commonwealth Scientific And Industrial Research Organisation Supplements for grazing ruminants
US3952115A (en) 1975-04-02 1976-04-20 The Procter & Gamble Company Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters
US4388327A (en) * 1981-10-30 1983-06-14 E. I. Du Pont De Nemours & Co. Method of increasing milk production of dairy cattle
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
US5871773A (en) * 1994-02-23 1999-02-16 Ajinomoto Co., Inc. Method for supplementing amino acid levels in ruminant animals
US5885610A (en) * 1997-03-04 1999-03-23 Zinpro Corporation By-pass rumen product
US6017563A (en) * 1997-07-25 2000-01-25 Novus International, Inc. Process for optimizing milk production
FR2785609B1 (en) * 1998-11-06 2000-12-15 Rhone Poulenc Nutrition Animal PROCESS FOR THE PREPARATION OF METHIONINE
FR2785773B1 (en) * 1998-11-13 2001-04-20 Rhone Poulenc Nutrition Animal USE OF METHIONINE ESTERS IN ANIMAL NUTRITION
US6545179B2 (en) * 2000-02-15 2003-04-08 Aventis Animal Nutrition, Sa Process for the production of methionine

Also Published As

Publication number Publication date
FR2785773A1 (en) 2000-05-19
BR9915290A (en) 2001-08-07
DE69917314T2 (en) 2005-06-23
ES2221486T3 (en) 2004-12-16
JP2002529108A (en) 2002-09-10
AU775693B2 (en) 2004-08-12
DK1128738T3 (en) 2005-01-24
EA200100531A1 (en) 2001-10-22
CN1301660C (en) 2007-02-28
ATE482627T1 (en) 2010-10-15
DK1442664T3 (en) 2011-01-10
US6872749B2 (en) 2005-03-29
JP4703853B2 (en) 2011-06-15
NO328761B1 (en) 2010-05-03
CA2348440C (en) 2008-09-16
KR100748051B1 (en) 2007-08-09
CN1326322A (en) 2001-12-12
PT1128738E (en) 2004-09-30
NZ511427A (en) 2003-07-25
EP1128738B9 (en) 2004-11-24
KR20060102352A (en) 2006-09-27
ATE266323T1 (en) 2004-05-15
BR9915290B1 (en) 2013-03-19
US20020103258A1 (en) 2002-08-01
AR021264A1 (en) 2002-07-03
AU2004224939A1 (en) 2004-11-25
PT1442664E (en) 2010-12-28
US20050187293A1 (en) 2005-08-25
NO20012355D0 (en) 2001-05-11
EP1442664A1 (en) 2004-08-04
US20040154549A1 (en) 2004-08-12
US6528541B2 (en) 2003-03-04
ID30016A (en) 2001-11-01
EA002558B1 (en) 2002-06-27
AU1385400A (en) 2000-06-05
CA2348440A1 (en) 2000-05-25
FR2785773B1 (en) 2001-04-20
MXPA01004747A (en) 2002-05-06
BR9917851B1 (en) 2013-07-02
TR200101323T2 (en) 2001-08-21
DE69917314D1 (en) 2004-06-17
US20010008904A1 (en) 2001-07-19
EP1128738A1 (en) 2001-09-05
EP1442664B1 (en) 2010-09-29
US6221909B1 (en) 2001-04-24
IL163773A0 (en) 2005-12-18
DE69942808D1 (en) 2010-11-11
US6372788B2 (en) 2002-04-16
US20030143260A1 (en) 2003-07-31
IL142955A0 (en) 2002-04-21
WO2000028835A1 (en) 2000-05-25
NO20012355L (en) 2001-07-13
KR20010099798A (en) 2001-11-09
AP1812A (en) 2007-12-28
MA25270A1 (en) 2001-10-01
KR100756572B1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
US20050187293A1 (en) Method for supplying bioavailable methionine to a cow
AU627111B2 (en) Method of raising meat producing animals to increase lean tissue development
US5087472A (en) Feed compositions for domestics animals containing hydroxymethylbutyrate
US4760090A (en) Method of feeding ketoisocaproate to cattle and sheep
USRE39403E1 (en) Method for supplying bioavailable methionine to a cow
US4835185A (en) Immunomodulator for improving commercial performance of domestic animals
HU182652B (en) Process for producing food-additives containing antibiotics
WO2001049128A1 (en) Dietary supplement
RU2053685C1 (en) Fodder for pigs
ES2351974T3 (en) A METHOD OF ADMINISTRATION OF METIONIN BIOD AVAILABLE TO A COW.
ZA200103539B (en) A method for supplying bioavailable methionine to a cow.
HU203040B (en) Process for producing weight-increasing composition containing 1-(3,5-dihydroxy-phenyl)-2-(terc-butyl-amino)-ethanol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010425

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020926

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADISSEO IRELAND LIMITED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040512

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69917314

Country of ref document: DE

Date of ref document: 20040617

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20040730

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20040402637

Country of ref document: GR

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20040512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2221486

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050215

NLR4 Nl: receipt of corrected translation in the netherlands language at the initiative of the proprietor of the patent
REG Reference to a national code

Ref country code: CH

Ref legal event code: PVP

ET1 Fr: translation filed ** revision of the translation of the patent or the claims
REG Reference to a national code

Ref country code: FR

Ref legal event code: GC

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: CH

Ref legal event code: PVP

REG Reference to a national code

Ref country code: FR

Ref legal event code: RG

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180920

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180920

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20180927

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20181018

Year of fee payment: 20

Ref country code: FI

Payment date: 20181018

Year of fee payment: 20

Ref country code: IE

Payment date: 20181022

Year of fee payment: 20

Ref country code: DK

Payment date: 20181025

Year of fee payment: 20

Ref country code: AT

Payment date: 20181029

Year of fee payment: 20

Ref country code: SE

Payment date: 20181115

Year of fee payment: 20

Ref country code: DE

Payment date: 20180927

Year of fee payment: 20

Ref country code: GR

Payment date: 20181016

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20181113

Year of fee payment: 20

Ref country code: ES

Payment date: 20181220

Year of fee payment: 20

Ref country code: BE

Payment date: 20181126

Year of fee payment: 20

Ref country code: CH

Payment date: 20181004

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69917314

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20191110

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20191109

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20191109

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20191110

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 266323

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191110

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191109

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191121

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191110

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191111